These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 20851512)

  • 1. Further support for active surveillance in the management of low-volume, low-grade prostate cancer.
    Albertsen P
    Eur Urol; 2010 Dec; 58(6):836-7. PubMed ID: 20851512
    [No Abstract]   [Full Text] [Related]  

  • 2. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment.
    Soloway MS; Soloway CT; Eldefrawy A; Acosta K; Kava B; Manoharan M
    Eur Urol; 2010 Dec; 58(6):831-5. PubMed ID: 20800964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial comment on: tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
    Gallina A
    Eur Urol; 2010 Apr; 57(4):639. PubMed ID: 19299073
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial comment on: tumor grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
    Yossepowitch O
    Eur Urol; 2010 Apr; 57(4):639-40. PubMed ID: 19299071
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.
    San Francisco IF; Werner L; Regan MM; Garnick MB; Bubley G; DeWolf WC
    J Urol; 2011 Feb; 185(2):471-6. PubMed ID: 21167525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
    Ladjevardi S; Sandblom G; Berglund A; Varenhorst E
    Eur Urol; 2010 Apr; 57(4):631-8. PubMed ID: 19299069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial comment on: prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy.
    Ciatto S
    Eur Urol; 2010 Apr; 57(4):630. PubMed ID: 19375847
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial comment on: prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy.
    Semjonow A
    Eur Urol; 2010 Apr; 57(4):629-30. PubMed ID: 19375846
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.
    Kulkarni GS; Lockwood G; Evans A; Toi A; Trachtenberg J; Jewett MA; Finelli A; Fleshner NE
    Cancer; 2007 Jun; 109(12):2432-8. PubMed ID: 17497649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer.
    Aizer AA; Paly JJ; Zietman AL; Nguyen PL; Beard CJ; Rao SK; Kaplan ID; Niemierko A; Hirsch MS; Wu CL; Olumi AF; Michaelson MD; D'Amico AV; Efstathiou JA
    J Clin Oncol; 2012 Sep; 30(25):3071-6. PubMed ID: 22851571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing prediction tools.
    Kattan MW
    Eur Urol; 2010 Apr; 57(4):569-70; discussion 574. PubMed ID: 20080334
    [No Abstract]   [Full Text] [Related]  

  • 12. Endocrine treatment: expected duration stage by stage.
    Schröder FH
    Prostate Suppl; 2000; 10():26-31. PubMed ID: 11056490
    [No Abstract]   [Full Text] [Related]  

  • 13. Effective treatment for early-stage prostate cancer--possible, necessary, or both?
    Smith MR
    N Engl J Med; 2011 May; 364(18):1770-2. PubMed ID: 21542749
    [No Abstract]   [Full Text] [Related]  

  • 14. Economic analysis of active surveillance for localized prostate cancer.
    Kim S; Dall'Era MA; Evans CP
    Curr Opin Urol; 2012 May; 22(3):247-53. PubMed ID: 22388666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural history of patients presenting biochemical recurrence after radical prostatectomy: some good news?
    Guillonneau BD; Fizazi K
    Eur Urol; 2011 Jun; 59(6):900-1. PubMed ID: 21419564
    [No Abstract]   [Full Text] [Related]  

  • 16. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.
    Eggener SE; Scardino PT; Carroll PR; Zelefsky MJ; Sartor O; Hricak H; Wheeler TM; Fine SW; Trachtenberg J; Rubin MA; Ohori M; Kuroiwa K; Rossignol M; Abenhaim L;
    J Urol; 2007 Dec; 178(6):2260-7. PubMed ID: 17936815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate biopsy: who, how and when. An update.
    Djavan B; Milani S; Remzi M
    Can J Urol; 2005 Feb; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
    Barocas DA; Cowan JE; Smith JA; Carroll PR;
    J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRI and surveillance.
    Ouzzane A; Puech P; Villers A
    Curr Opin Urol; 2012 May; 22(3):231-6. PubMed ID: 22388665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical recurrence following robot-assisted radical prostatectomy: analysis of 1384 patients with a median 5-year follow-up.
    Menon M; Bhandari M; Gupta N; Lane Z; Peabody JO; Rogers CG; Sammon J; Siddiqui SA; Diaz M
    Eur Urol; 2010 Dec; 58(6):838-46. PubMed ID: 20869162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.